SIC
ABBV icon

Samalin Investment Counsel’s AbbVie ABBV Stock Holding History

Samalin Investment Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$761K Sell
3,023
-431
-12% -$92.7K 0.24% 100
2026
Q1 		$751K Buy
3,454
+82
+2% +$18.2K 0.27% 112
2025
Q4 		$770K Sell
3,372
-18
-0.5% -$4.1K 0.27% 105
2025
Q3 		$785K Buy
3,390
+64
+2% +$13K 0.27% 106
2025
Q2 		$617K Sell
3,326
-255
-7% -$47.4K 0.24% 123
2025
Q1 		$750K Buy
3,581
+288
+9% +$56K 0.3% 98
2024
Q4 		$585K Buy
3,293
+5
+0.2% +$919 0.25% 114
2024
Q3 		$649K Sell
3,288
-2,063
-39% -$385K 0.28% 107
2024
Q2 		$918K Sell
5,351
-17
-0.3% -$2.82K 0.43% 57
2024
Q1 		$978K Sell
5,368
-61
-1% -$10.5K 0.47% 59
2023
Q4 		$841K Sell
5,429
-17
-0.3% -$2.48K 0.43% 64
2023
Q3 		$812K Sell
5,446
-53
-1% -$7.78K 0.47% 59
2023
Q2 		$741K Sell
5,499
-307
-5% -$45K 0.4% 69
2023
Q1 		$925K Sell
5,806
-15
-0.3% -$2.29K 0.56% 50
2022
Q4 		$941K Buy
5,821
+19
+0.3% +$2.91K 0.59% 46
2022
Q3 		$779K Sell
5,802
-111
-2% -$15.9K 0.57% 50
2022
Q2 		$906K Sell
5,913
-3,212
-35% -$491K 0.64% 46
2022
Q1 		$1.48M Sell
9,125
-28
-0.3% -$4.07K 0.9% 25
2021
Q4 		$1.24M Sell
9,153
-1,345
-13% -$159K 0.74% 30
2021
Q3 		$1.13M Buy
10,498
+175
+2% +$20K 0.74% 29
2021
Q2 		$1.16M Buy
10,323
+88
+0.9% +$9.91K 0.75% 26
2021
Q1 		$1.11M Buy
10,235
+341
+3% +$36.5K 0.74% 29
2020
Q4 		$1.06M Sell
9,894
-327
-3% -$31.4K 0.8% 27
2020
Q3 		$895K Buy
10,221
+7,465
+271% +$703K 0.8% 30
2020
Q2 		$270K Sell
2,756
-171
-6% -$15.1K 0.28% 116
2020
Q1 		$223K Sell
2,927
-145
-5% -$12.4K 0.3% 103
2019
Q4 		$272K Buy
+3,072
New +$255K 0.23% 119

Other funds holding ABBV

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return

Samalin Investment Counsel's ABBV Position: Q2 2026 in Review

Samalin Investment Counsel reduced its AbbVie (ABBV) stake by 12% in Q2 2026, selling an estimated $92.7K and leaving 3,023 shares worth $761K. The position accounts for 0.24% of the portfolio, ranked #100.

Samalin Investment Counsel first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.48M in Q1 2022. 1,885 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Samalin Investment Counsel held 3,023 shares of AbbVie worth $761K as of Q2 2026.
  • Samalin Investment Counsel sold 431 AbbVie shares in Q2 2026, an estimated $92.7K.
  • AbbVie made up 0.24% of Samalin Investment Counsel's portfolio in Q2 2026, its #100 holding.
  • Samalin Investment Counsel first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Samalin Investment Counsel's AbbVie position peaked at $1.48M in Q1 2022.
  • 1,885 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Samalin Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.